Search

Your search keyword '"Olaizola, Paula"' showing total 139 results

Search Constraints

Start Over You searched for: Author "Olaizola, Paula" Remove constraint Author: "Olaizola, Paula"
139 results on '"Olaizola, Paula"'

Search Results

3. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma

5. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

6. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

8. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma

9. A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease

11. Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma

12. Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms

13. Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells

14. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by inhibiting multi-organ bile acid transport and shows translational relevance to human

15. Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis

16. KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor

18. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

19. 178 - THERAPEUTIC POTENTIAL OF TARGETING PROTEIN HYPER- SUMOYLATION IN CHOLANGIOCARCINOMA

20. 159 - KLF5 UPREGULATION IS A COMMON EVENT IN CHOLANGIOCARCINOMA, ACTING AS AN ONCOGENE AND CONSTITUTING A BAD PROGNOSTIC FACTOR

21. 177 - NOVEL PLATINUM-BASED CHEMOTHERAPEUTIC AGENTS HALT CHOLANGIOCARCINOMA PROGRESSION THROUGH THE INDUCTION OF INTERSTRAND DNA BREAKS, PREVENTING DNA REPAIR MECHANISMS

22. LIQUID BIOPSY PROTEINS AS PSC-SPECIFIC AND PAN-CCA BIOMARKERS OF CANCER RISK, EARLY DIAGNOSIS AND SURVIVAL MIRRORING TUMOR CELLS

23. Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma

25. The uptake of extracellular lipids promotes cholangiocarcinoma progression

26. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

27. Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis

29. Proceso de toma de decisiones en la transición al cuidado hospice. Hospitalidad compasiva en el final de la vida

30. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

31. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

32. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

33. Primary cilia loss promotes reactivation of morphogenesis and cyst-fission through a deregulated TGFβ-ECM-Integrin axis in polycystic liver disease

34. Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

35. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

36. Inhibition of NAE‐dependent protein hyper‐NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease

38. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

39. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

40. Targeting UBC9-Mediated Protein Hyper-SUMOylation in Cystic Cholangiocytes Halts Polycystic Liver Disease in Experimental Models

41. SAT-244 - Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis

42. SAT-238 - Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells

43. SAT-223 - Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma

44. SAT-226 - KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor

45. SAT-212 - Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms

46. OS-074-YI - A3907, a systemic ASBT inhibitor, improves cholestasis in mice by inhibiting multi-organ bile acid transport and shows translational relevance to human

47. Lignins from Agroindustrial by-Products as Natural Ingredients for Cosmetics: Chemical Structure and In Vitro Sunscreen and Cytotoxic Activities

48. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

49. Pathogenesis of Cholangiocarcinoma

Catalog

Books, media, physical & digital resources